Leukemia Cancer News - Return to Menu
NCCN Releases Acute Myeloid Leukemia and Chronic Myelogenous Leukemia Chapters of the NCCN Drugs & Biologics Compendium
JENKINTOWN, Pa.--(BUSINESS WIRE)--Feb. 28, 2005--The National Comprehensive Cancer Network (NCCN) announces the release of Chapters 4 and 5 of the NCCN Drugs & Biologics Compendium(TM): Acute Myeloid Leukemia and Chronic Myelogenous Leukemia.
"The NCCN Drugs & Biologics Compendium contains authoritative and definitive information about the appropriate use of drugs and biologics in the care of patients with leukemia - information that decision-makers at insurance and managed care companies and pharmacy benefits managers can use to establish coverage policy," said William T. McGivney, Ph.D., CEO of the NCCN. "With the release of the leukemia chapters, NCCN utilization information adds to a long list of scientific, evaluative products to facilitate decision-making about appropriate cancer care."
The NCCN Drugs & Biologics Compendium outlines the appropriate uses of drugs and biologics in the care of cancer patients, as derived from the NCCN Clinical Practice Guidelines in Oncology(TM) -- recognized and applied nationally as the standard for clinical policy in oncology. Listed uses include FDA-approved indications as well as those beyond FDA labeling. As with the guidelines, the Compendium spans the continuum of cancer care from early stage to advanced stage disease, and from supportive to palliative care.
Oncology care professionals can visit www.nccn.org to access the most up-to-date version of the NCCN Drugs & Biologics Compendium online or to request a free printed copy.
For more information on the NCCN Drugs & Biologics Compendium and other NCCN programs, please contact NCCN at 215-690-0254 or at www.nccn.org.
The National Comprehensive Cancer Network (NCCN), an alliance of 19 of the world's leading cancer centers, is an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines.
These guidelines are the standard for clinical policy in oncology. NCCN's complete spectrum of programs emphasizes improving the quality, effectiveness, and efficiency of oncology practice. Programs include: Clinical Practice Guidelines in Oncology(TM), Drugs & Biologics Compendium(TM), Treatment Guidelines for Patients, the Journal of the National Comprehensive Cancer Network, Leukemia Resource Line, educational conferences and symposia for clinicians, Oncology Outcomes Project, Clinical Trials Network, Cancer Case Manager, and collaborations with managed care organizations.
NCCN member institutions include:
-- City of Hope Cancer Center
-- Dana-Farber/Partners CancerCare
-- Duke Comprehensive Cancer Center
-- Fox Chase Cancer Center
-- Huntsman Cancer Institute at the University of Utah
-- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
-- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University
-- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
-- Memorial Sloan-Kettering Cancer Center
-- H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida
-- Roswell Park Cancer Institute
-- St. Jude Children's Research Hospital/University of Tennessee Cancer Institute
-- Stanford Hospital & Clinics
-- University of Alabama at Birmingham Comprehensive Cancer Center
-- UCSF Comprehensive Cancer Center
-- University of Michigan Comprehensive Cancer Center
-- UNMC Eppley Cancer Center at The Nebraska Medical Center
-- The University of Texas M.D. Anderson Cancer Center
For more information, visit www.nccn.org.
National Comprehensive Cancer Network (NCCN)
Susan Sommerville, 215-690-0254